Insmed Q3 revenue tops $524 million; Brinsupri, Arikayce guidance raised, Japan launch underwayNov 10M&AamikacinbrensocatibUpdated
United Therapeutics registers two SUMMIT trials of inhaled treprostinil SMI for PH-COPDNov 6Weekly roundup, 2 itemstreprostinilUnited Therapeutics
Insmed's Phase 3 PALM-PPF trial of inhaled TPIP in pulmonary fibrosis is recruitingNov 2Trial updateInsmed Incorporatedtreprostinil palmitil inhalation
United Therapeutics posts TETON-2 Phase 3 results for inhaled Tyvaso in IPFOct 15Trial updatetreprostinilUnited Therapeutics
Alaunos acquires Velaris Therapeutics, lines up $350 million PIPE financingOct 13M&AAlaunos Therapeutics, Inc.Liquidia Corp
United Therapeutics: TYVASO DPI (NDA214324) SUPPL 7 approvedSep 23Regulatory decisiontreprostinilUnited TherapeuticsRecord notice
Insmed registers Phase 3 trial of inhaled TPIP for progressive pulmonary fibrosisSep 4Trial updateInsmed Incorporatedtreprostinil palmitil inhalation
FDA grants Fast Track designation to Liquidia's YUTREPIA for SSc-related Raynaud's phenomenonSep 3Regulatory milestoneLiquidia Corptreprostinil
Liquidia reports YUTREPIA sales growth, begins enrollment in L606 pivotal studyAug 12Quarterly updateLiquidia Corptreprostinil
United Therapeutics files two rare pulmonary disease NDAs, sets sights on approvals in 2027Aug 5Quarterly updateralinepagtreprostinil
FDA approves manufacturing supplement for Orenitram tablets from UNITED THERAPAug 4Regulatory decisiontreprostinilUnited Therapeutics
Insmed reports 12-month OLE data for TPIP in pulmonary arterial hypertensionJul 16Clinical readoutInsmed Incorporated